Catalent believes that the addition of this capability from the Maryland firm will help its position in tapping on strong industry tailwinds in the market for gene therapies. Catalent has acquired the gene therapy contract development and manufacturing organisation Paragon Bioservices in an all-cash deal worth $1.2bn. The company said it had signed a letter of intent with Paragon to develop its first product for use against cancer called PD-1. Paragon, which specialises in the development of adeno-associated virus vectors, is expected to strengthen Catalent's position in the market for gene therapies while also expanding its research and manufacturing capabilities.
Catalent has acquired the gene therapy contract development and manufacturing organisation Paragon Bioservices in an all-cash deal worth $1.2bn. The company said it had signed a letter of intent with Paragon to develop its first product for use against cancer called PD-1. Paragon, which specialises in the development of adeno-associated virus vectors, is expected to strengthen Catalent's position in the market for gene therapies while also expanding its research and manufacturing capabilities.